Effect of oral and panchkrma Therapy on the Growth concern Harmone in cerebral palsy Children

Effect of oral and panchkrma Therapy on growth concern Harmone in cerebral palsy Children - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084510

Enrollment

Registered

2025-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G80-G83- Cerebral palsy and other paralytic syndromes

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.two to sixteen years of cerebral palsy children irrespective of sex and who have not taken panchkarma therapy. 2.children with developmental disability of both physical and mental (delayed milestone)

Exclusion criteria

Exclusion criteria: 1. Cerebral palsy children who have taken panchkarma therapy before ragistration. 2. Children associates with congenital and genetic disorder. 3.children with other disease such as diabetic acute infection or other life threatening disorders. 4. Patient gaurdian or parent are unwilling to participate in the study

Design outcomes

Primary

Measure	Time frame
To investigate panchkarma therapy impact on hormone levels, specifically focusing on thyroid hormone (T3,T4,TSH) progesterone testosterone and growth hormone levels in cerebral palsy children by assessing change in their levels before and after therapyTimepoint: To investigate panchkarma therapy impact on hormone levels, specifically focusing on thyroid hormone (T3,T4,TSH) progesterone testosterone and growth hormone levels in cerebral palsy children by assessing change in their levels before and after therapy	—

Measure

Time frame

To investigate panchkarma therapy impact on hormone levels, specifically focusing on thyroid hormone (T3,T4,TSH) progesterone testosterone and growth hormone levels in cerebral palsy children by assessing change in their levels before and after therapyTimepoint: To investigate panchkarma therapy impact on hormone levels, specifically focusing on thyroid hormone (T3,T4,TSH) progesterone testosterone and growth hormone levels in cerebral palsy children by assessing change in their levels before and after therapy

—

Secondary

Measure	Time frame
To explore the effect of (clinical outcome) panchkarma therapy on growth and developmentTimepoint: One month	—

Countries

India

Contacts

Public ContactBrijmohan singh

Department of kaumarbhritya Balaroga faculty of Ayurveda IMS bhu

bms@bhu.ac.in9415286910

Outcome results